CA-ARMIS
12.2.2024 14:01:29 CET | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, today announced that it has been named a Top Performer in the 2024 Best in KLAS Software & Services Report for Healthcare IoT Security for the second year in a row. The Best in KLAS report recognizes software and services companies that excel in helping healthcare professionals improve patient care.
“This recognition from KLAS which is based solely on customer reviews is a true testament to our ongoing commitment to protecting the attack surfaces of healthcare organizations,” said Mohammad Waqas, CTO of Healthcare at Armis. “I want to thank every Armis customer who took the time this year to share with KLAS their experience with Armis CentrixTM for Medical Device Security. Your feedback is instrumental in helping us continuously improve our solutions and deliver the best possible value to the healthcare community.”
The 2024 Best in KLAS report, based on independent feedback from healthcare providers in North America, evaluates vendors across six key performance areas: culture, loyalty, operations, product, relationship and value. Armis achieved an outstanding overall score, demonstrating excellence in every category and solidifying the company’s position as a leader in Healthcare IoT Security.
When asked about Armis, customers shared the following anonymized comments with KLAS in review of the company’s solution:
- “Given the nature of how sensitive and aware we have all become to some of the hazards surrounding cybersecurity and cyber risks associated with penetration into personal health information through many different avenues of medical devices and applications, the Armis application is robust in being able to see all network-connected devices. It is really incredible to see the amount of horsepower that the Armis platform brings to the table for us. The product really is a great tool. Not only can the reporting piece identify connected devices but it is able to identify what type of device something is through the product's algorithms. The product is able to determine what the make, model, and serial number are, and in some cases, what operating system the device is functioning on. Recently, we had an issue with updating the security on anything that was still running on something other than Windows 10, and through the Armis system, we were able to see how many devices were reporting through the application that were not up to Windows 10. With the reporting structure, we now have a line of sight into many things we didn't know about.” - Director, April 2023
- “Armis does very well with implementations. They are very knowledgeable about their products. They have experts on their team, so if we need some help with a configuration, they have resources available that are on standby typically to help and engage in troubleshooting.” - Analyst/Coordinator, April 2023
- “In general, Armis regularly updates their platform and gives good notifications about new enhancements and new features. They back those notifications up with written material and videos, as well as live sessions if we are lucky enough to find the time to attend them. It is good that the vendor is constantly adding new features and new capabilities to the product.” - Analyst/Coordinator, September 2023
In July 2023, Armis was rated the best-performing cross-industry vendor in the KLAS Healthcare IoT Security 2023 report for its deep coverage of IoT, OT, IoMT and IT across all verticals.
In the past year, Armis has continued to deepen its commitment to securing healthcare organizations. Combining the power of Armis CentrixTM, the cyber exposure management platform, and the Armis AI-powered Asset Intelligence Engine, Armis has reinforced its healthcare-specific capabilities which help to provide complete visibility and security for all medical devices, clinical assets and the entire healthcare ecosystem with zero disruptions to patient care.
Armis is a sponsor of HIMSS 2024, taking place in Orlando, FL March 11-15. Stop by Armis’ booth #1621 in the CyberSecurity Command Center or visit the team in the Main Walkway at booth #1048. At HIMSS, Armis’ CTO of Healthcare, Mohammad Waqas, will speak to “Building a Comprehensive Healthcare Security Program for Next-Gen Patient Care.” This session will be held on Tuesday, March 12th from 10:15am - 10:30am EDT in the Orange County Convention Center, Theatre A.
To read the KLAS report, please visit: 2024 Best in KLAS - Software & Services
To learn more about Armis CentrixTM for Medical Device Security, go to: https://www.armis.com/platform/armis-centrix-for-medical-device-security/
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
About KLAS Research
KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212843101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom